**Part 4**

**Management and Therapy** 

142 Challenges in Rheumatology

Schmidt, WA. & Blockmans, D. (2005). Use of ultrasonography and positron emission

Schmidt, WA, & Gromnica-Ihle, E. (2005). What is the best approach to diagnosing large-

Schmidt, WA. Current diagnosis and treatment of temporal arteritis. (2006), Current

Schmidt, WA., Seifert, A., Gromnica-Ihle, E., Krause, A. & Natusch, A (2008), Ultrasound of

Siemssen SJ. (1987). On the occurrence of necrotising lesions in arteritis temporalis: review

Suelves, AM., Espana-Gregori, E., Tembl, J., Rohrweck, S., Millan, JM. & Diaz-Llopis, M.

Tato, F.& Hoffmann U. (2006). Clinical presentation and vascular imaging in giant cell

Vinckier, L., Hatron, PY., Gadenne, C.,, Catteau, MH., Gosset, D.& Devulder, B. (1989).

No. 4,(November 2010), pp. 1383-4, ISSN 1177-5483

Medicine, Vol. 13, No. 2, (2008), pp. 127-40, ISSN 1358-863X

6, Suppl 47, (Novembre-December 2007), pp.137-41, 0392-856X

Plastic Surgery, vol. 40, No. 1, (Jauary 1987), pp. 73-82, ISSN 0007-1226 Slavin, ML. (1986). Brow droop after superficial temporal artery biopsy. Archives of Ophthalmology, Vol. 104, No. 8, (Augut 1986), p. 1127, ISSN 0003-9950 Stanson, AW. (2000). Imaging findings in extracranial (giant cell) temporal arteritis. Clinical

1, (January 2005), pp. 9-15, ISSN 1040-8711

(April 2005), pp. 223-42, ISSN 1521-6942

2009), pp. 383-5, ISSN 1462-0332

pp. S43-8, ISSN 0392-856X

51, ISSN 1092-8464

tomography in the diagnosis and assessment of large-vessel vasculitis, Vol. 17, No.

vessel vasculitis? Best Practice & Research Clinical Rheumatology, Vol. 19, No. 2,

Treatment Options in Cardiovascular Medicine, Vol.8, No. 2, ( April 2006), pp. 145-

proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. Rheumatology (Oxford), Vol. 47, No. 1, (Jnuary 2008), SSN 1462-0332 Schmidt, WA., Krause, A., Schicke, B., Kuchenbecker, J, & Gromnica-Ihle, E. (2009). Do

temporal artery duplex ultrasound findings correlate with ophthalmic complications in giant cell arteritis? Rheumatology (Oxford), Vol. 48, No. 4, (April

of the literature with a note on the potential risk of a biopsy. British Journal of

and Experimental Rheumatology, Vol. 18, No. 4 , Suppl 20, ( Julyu-August 2000),

(2010). Doppler ultrasound and giant cell arteritis.Clinical Ophthalmology, Vol. 25,

arteritis of the femoropopliteal and tibioperoneal arteries. Analysis of four cases. Journal of Vascular Surgery, Vol. 44, No 1, (July 2006), pp. 176-82, ISSN 0741-5214 Tato, F. & Hoffmann U. Giant cell arteritis: a systemic vascular disease. (2008). Vascular

Significance of arterial Doppler in Horton's disease. Prospective study of 59 case reports. Journal des Maladies Vasculaires, Vol. 14, Suppl C, (1989), ISSN 0398-0499 Walter, MA., Melzer, RA., Schindler, C., Muller-Brand, J., Tyndal,l A & Nitzsche EU (2005).

The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. European Journal of Nuclear Medicine and Molecular Imaging, Vol. 32, No. 6, (june 2005), pp. 674-81, ISSN 1619-7070 Warrington, KJ. & Matteson, EL. Management guidelines and outcome measures in giant

cell arteritis (GCA). (2007). Clinical and Experimental Rheumatology, Vol. 25, No.

Weyand, CM. & Goronzy, JJ. (2003). Giant-cell arteritis and polymyalgia rheumatica. Annals of Internal Medicine, Vol.1 39, No. 6, (September 2003), pp. 505-15, ISSN 1539-3704

**8** 

*Spain* 

**Perioperative Management of Non-Biological** 

Patients with rheumatoid arthritis (RA) or other inflammatory arthropathies often require orthopedic surgery, and the management of their medical treatments during the perioperative period is an important issue. The two main concerns during this period are

These patients receive multidisciplinary care from orthopedic surgeons, rehabilitators and rheumatologists (1). Before orthopedic surgery, the activity of the arthropathy and the nonbiological and biological therapies of patients must be taken into consideration for an optimal outcome with no infectious or wound-healing complications. Good clinical and biological control of the disease must be obtained before the surgery, and effective

The management of non-biological (immunosuppressive or immunomodulatory) and biological therapies in orthopedic surgery patients remains controversial. This chapter focuses on disease-modifying anti-rheumatic drugs (DMARDs) and biological therapies (see table 1). Although corticosteroids are immunosuppressants, protocols for their replacement or supplementation are well established in the literature and are not addressed here (3). DMARDs and especially biological therapies are the subject of multiple consultations between rheumatologists and orthopedists or anesthetists before surgery. The objective of this chapter is to discuss current protocols for the application of these treatments before and after orthopedic surgery, based on the best available scientific evidence or, in its absence, on

Until five years ago, there was a tendency to withdraw MTX at around two weeks before surgery, based on reports in various retrospective studies of a higher risk of postoperative complications, especially infections (4). However, a well-designed prospective study by Grennan et al. (5) in 388 patients concluded that the continuation of MTX treatment did not

the risk of infection and wound healing complications.

coordination between surgeon and rheumatologist is essential (2).

**2. Disease-modifying anti-rheumatic drugs (DMARDS)** 

**1. Introduction** 

accepted recommendations.

**2.1 Methotrexate (MTX)** 

**and Biological Therapies in Rheumatic** 

Juan Salvatierra Ossorio, Magdalena Peregrina-Palomares, Francisco O´Valle Ravassa and Pedro Hernandez-Cortes *Department of Orthopedic Surgery, San Cecilio University Hospital* 

*University of Granada, Granada* 

**Patients Undergoing Orthopedic Surgery** 
